skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: ClinicalKey remover assunto: Leukemia, Myeloid, Acute - Drug Therapy remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
Material Type:
Artigo 		Adicionar ao Meu Espaço

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Lin, Tara L. ; Rizzieri, David A. ; Ryan, Daniel H. ; Schiller, Gary J. ; Kolitz, Jonathan E. ; Uy, Geoffrey L. ; Hogge, Donna E. ; Solomon, Scott R. ; Wieduwilt, Matthew J. ; Ryan, Robert J. ; Faderl, Stefan ; Cortes, Jorge E. ; Lancet, Jeffrey E.

Blood advances, 2021-03, Vol.5 (6), p.1719-1728 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
2
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Material Type:
Artigo 		Adicionar ao Meu Espaço

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

de Botton, Stéphane ; Cluzeau, Thomas ; Vigil, Carlos ; Cook, Rachel J. ; Rousselot, Philippe ; Rizzieri, David A. ; Liesveld, Jane L. ; Fenaux, Pierre ; Braun, Thorsten ; Banos, Anne ; Jurcic, Joseph G. ; Sekeres, Mikkael A. ; Savona, Michael R. ; Roboz, Gail J. ; Bixby, Dale ; Madigan, Kate ; Volkert, Angela ; Stephens, Kristin ; Kang-Fortner, Qing ; Baker, Kristen ; Paul, Sofia ; McKeown, Michael ; Carulli, John ; Eaton, Matthew ; Hodgson, Graeme ; Fiore, Christopher ; Kelly, Michael J. ; Roth, David A. ; Stein, Eytan M.

Blood advances, 2023-05, Vol.7 (9), p.1858-1870 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Issa, Jean-Pierre J, Prof ; Roboz, Gail, Prof ; Rizzieri, David, Prof ; Jabbour, Elias, MD ; Stock, Wendy, Prof ; O'Connell, Casey, MD ; Yee, Karen, MD ; Tibes, Raoul, MD ; Griffiths, Elizabeth A, MD ; Walsh, Katherine, MD ; Daver, Naval, MD ; Chung, Woonbok, PhD ; Naim, Sue, BS ; Taverna, Pietro, PhD ; Oganesian, Aram, PhD ; Hao, Yong, MD ; Lowder, James N, MD ; Azab, Mohammad, MD ; Kantarjian, Hagop, Prof

The lancet oncology, 2015-09, Vol.16 (9), p.1099-1110 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Kantarjian, Hagop M ; Roboz, Gail J ; Kropf, Patricia L ; Yee, Karen W L ; O'Connell, Casey L ; Tibes, Raoul ; Walsh, Katherine J ; Podoltsev, Nikolai A ; Griffiths, Elizabeth A ; Jabbour, Elias ; Garcia-Manero, Guillermo ; Rizzieri, David ; Stock, Wendy ; Savona, Michael R ; Rosenblat, Todd L ; Berdeja, Jesus G ; Ravandi, Farhad ; Rock, Edwin P ; Hao, Yong ; Azab, Mohammad ; Issa, Jean-Pierre J

The lancet oncology, 2017-10, Vol.18 (10), p.1317-1326 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia

Advani, Anjali S. ; Tse, William ; Li, Hong ; Jia, Xuefei ; Elson, Paul ; Cooper, Brenda ; Ali-Osman, Francis ; Park, Jino ; Rao, Arati V. ; Rizzieri, David A. ; Wang, Eunice S. ; Cotta, Claudiu V. ; Kalaycio, Matt ; Sobecks, Ronald M. ; Rouphail, Basel ; Maciejewski, Jaroslaw P. ; Fensterl, Jaime ; Carew, Jennifer S. ; Foster, Bethany ; Rush, Mary Lynn ; Tripp, Barbara ; Adams, Donna ; Corrigan, Donna ; Griffiths, Elizabeth A. ; Sekeres, Mikkael A.

Clinical lymphoma, myeloma and leukemia, 2021-02, Vol.21 (2), p.113-118 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
6
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission

Farag, Sherif S ; Maharry, Kati ; Zhang, Mei-Jie ; Pérez, Waleska S ; George, Stephen L ; Mrózek, Krzysztof ; DiPersio, John ; Bunjes, Donald W ; Marcucci, Guido ; Baer, Maria R ; Cairo, Mitchell ; Copelan, Edward ; Cutler, Corey S ; Isola, Luis ; Lazarus, Hillard M ; Litzow, Mark R ; Marks, David I ; Ringdén, Olle ; Rizzieri, David A ; Soiffer, Robert ; Larson, Richard A ; Tallman, Martin S ; Bloomfield, Clara D ; Weisdorf, Daniel J

Biology of blood and marrow transplantation, 2011-12, Vol.17 (12), p.1796-1803

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
7
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia

Morris, Tod A ; DeCastro, Carlos M ; Diehl, Louis F ; Gockerman, Jon P ; Lagoo, Anand S ; Li, Zhiguo ; Moore, Joseph O ; Rizzieri, David A ; Rao, Arati V

Leukemia research, 2013-01, Vol.37 (1), p.28-31 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia
Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Giles, Francis ; Rizzieri, David ; Ravandi, Farhad ; Swords, Ronan ; Jacobsen, Tove Flem ; O’Brien, Susan

Leukemia research, 2012-04, Vol.36 (4), p.e71-e73 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Ravandi, Farhad, Prof ; Ritchie, Ellen K, MD ; Sayar, Hamid, MD ; Lancet, Jeffrey E, MD ; Craig, Michael D, MD ; Vey, Norbert, Prof ; Strickland, Stephen A, MD ; Schiller, Gary J, Prof ; Jabbour, Elias, MD ; Erba, Harry P, Prof ; Pigneux, Arnaud, Prof ; Horst, Heinz-August, Prof ; Recher, Christian, Prof ; Klimek, Virginia M, MD ; Cortes, Jorge, Prof ; Roboz, Gail J, MD ; Odenike, Olatoyosi, MD ; Thomas, Xavier, MD ; Havelange, Violaine, MD ; Maertens, Johan, Prof ; Derigs, Hans-Günter, Prof ; Heuser, Michael, MD ; Damon, Lloyd, Prof ; Powell, Bayard L, Prof ; Gaidano, Gianluca, Prof ; Carella, Angelo-Michele, MD ; Wei, Andrew, MBBS ; Hogge, Donna, Prof ; Craig, Adam R, MD ; Fox, Judith A, PhD ; Ward, Renee, MD ; Smith, Jennifer A, PhD ; Acton, Gary, MD ; Mehta, Cyrus, Prof ; Stuart, Robert K, MD ; Kantarjian, Hagop M, Prof

The lancet oncology, 2015-09, Vol.16 (9), p.1025-1036 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia
FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia

Grunwald, Michael R ; Levis, Mark J

Seminars in hematology, 2015-07, Vol.52 (3), p.193-199 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (60)

Data de Publicação 

De até
Refinar
  1. Antes de2008  (3)
  2. 2008Até2010  (12)
  3. 2011Até2013  (7)
  4. 2014Até2017  (22)
  5. Após 2017  (19)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.